SCHEMBL4624850

SCHEMBL4624850

O=CN1CCN(c2ccc(C=C3C(=O)Nc4ccccc43)cc2)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 8/20 1.00
ERBB2 P04626 3/20 1.00
RET P07949 3/20 1.00
FGFR1 P11362 1/20 1.00
KIT P10721 2/20 0.70
AURKB Q96GD4 2/20 0.70
IGF1R P08069 2/20 0.70
FLT3 P36888 1/20 0.58
PLK4 O00444 1/20 0.58
PLK1 P53350 1/20 0.58
KDR P35968 1/20 0.58
MEN1 O00255 2/20 0.54
ALDH1A1 P00352 2/20 0.54
APP P05067 2/20 0.54
MAPT P10636 2/20 0.54
MAPK1 P28482 2/20 0.54
SNCA P37840 2/20 0.54
KMT2A Q03164 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
CTRC Q99895 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20898243 1.00 PDGFRB (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL29496459 1.00 PDGFRB (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL141892 1.00 PDGFRB (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL14519135 0.88 ERBB2 (0.97) PDGFRBERBB2RETFGFR1KIT
SCHEMBL6001567 0.88 ERBB2 (0.97) PDGFRBERBB2RETFGFR1KIT
SCHEMBL6001605 0.87 ERBB2 (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL20399720 0.86 ERBB2 (0.79) PDGFRBERBB2RETFGFR1KIT
SCHEMBL1452716 0.86 PDGFRB (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL1452713 0.86 PDGFRB (1.00) PDGFRBERBB2RETFGFR1KIT
SCHEMBL5702159 0.86 ERBB2 (0.79) PDGFRBERBB2RETFGFR1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372621-B1 NOVEL USE OF TYROSINE KINASE FRK INHIBITOR INNOVENTUS PROJECT AB (SE) 2008-06-11 EP claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
WO-2005044181-A2 PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-05-19 WO claimed
EP-0931152-A2 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE Sugen, Inc. (US) 1999-07-28 EP claimed
WO-1998007835-A9 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE 1998-06-11 WO claimed
WO-1998007835-A2 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE SUGEN, INC. (US) 1998-02-26 WO claimed
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2024-06-04 US disclosed
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2024-02-29 US disclosed
CN-116963718-A Composition for ophthalmic care 瑞比奥科技公司 2023-10-27 CN disclosed
CN-116917464-A Platelet alpha particles for delivery of multiple proteins 希思特思医疗保健公司 2023-10-20 CN disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20230090520-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2023-03-23 US disclosed
US-20030069421-A1 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors SUGEN, INC. 2003-04-10 US disclosed
US-6486185-B1 3-heteroarylidene-2-indolinone protein kinase inhibitors SUGEN, INC. 2002-11-26 US disclosed
EP-0934931-A2 3-Benzylidene-2-indolinones and their analogues as tyrosine kinase activity modulators Sugen, Inc. (US) 1999-08-11 EP disclosed
EP-0931152-A2 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE Sugen, Inc. (US) 1999-07-28 EP disclosed
WO-1998007835-A9 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE 1998-06-11 WO disclosed
WO-1998007835-A2 CRYSTAL STRUCTURES OF A PROTEIN TYROSINE KINASE SUGEN, INC. (US) 1998-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 PDGFRB 2138/4885ERBB2 491/4885RET 1/4885
US-20030069421-A1 3-(Piperazinylbenzylidenyl)-2-indolinone compounds and derivatives as protein tyrosine kinase inhibitors ABL1, ERBB2, PTK2B PDGFRB 280/4885ERBB2 2/4885RET 44/4885
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 PDGFRB 4421/4885ERBB2 4314/4885RET 3720/4885
US-11998545-B2 Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF PDGFRB 1563/4885ERBB2 135/4885RET 1/4885
US-20230090520-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PDGFRB 1563/4885ERBB2 135/4885RET 1/4885
US-20240066029-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF PDGFRB 1563/4885ERBB2 135/4885RET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.